When it comes to assessing the value of medicines, conventional cost-effectiveness analysis (CEA) methods typically only account for the value of quality-adjusted life years (QALYs) and health care costs and miss important elements of value that matter to patients and society. The outcomes that matter to patients should matter to everyone.